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Delaying histone deacetylase response to injury
accelerates conversion into repair Schwann cells
and nerve regeneration
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The peripheral nervous system (PNS) regenerates after injury. However, regeneration is often
compromised in the case of large lesions, and the speed of axon reconnection to their target
is critical for successful functional recovery. After injury, mature Schwann cells (SCs) convert
into repair cells that foster axonal regrowth, and redifferentiate to rebuild myelin. These
processes require the regulation of several transcription factors, but the driving mechanisms
remain partially understood. Here we identify an early response to nerve injury controlled
by histone deacetylase 2 (HDAC2), which coordinates the action of other chromatin-
remodelling enzymes to induce the upregulation of Oct6, a key transcription factor for SC
development. Inactivating this mechanism using mouse genetics allows earlier conversion
into repair cells and leads to faster axonal regrowth, but impairs remyelination. Consistently,
short-term HDAC1/2 inhibitor treatment early after lesion accelerates functional recovery
and enhances regeneration, thereby identifying a new therapeutic strategy to improve PNS
regeneration after lesion.
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A
xons of the peripheral nervous system (PNS) have a high
capacity of regeneration after lesion, in contrast to axons
of the central nervous system (CNS), which poorly
regenerate. This is due to intrinsic regenerative properties of
PNS neurons, and to a large extent to extrinsic factors that allow
and promote axonal regeneration in the PNS1. Schwann cells
(SCs), the PNS myelinating glia, hold major functions in creating
a favourable environment for axonal regrowth, stimulating
axon outgrowth after lesion, and rebuilding myelin sheaths of
regenerated axons2. Upon lesion, mature SCs convert into a
repair cell phenotype that resembles the immature SC stage in
some but not all aspects1–3. Indeed, repair SCs downregulate
myelin proteins and pro-myelinating factors such as Krox20 to
dedifferentiate and demyelinate, but they also simultaneously
activate a repair programme that promotes axonal regrowth and
survival, as well as axon debris and myelin removal4. The
transcription factor cJun plays a central role in controlling these
processes: cJun is strongly upregulated in SCs after a PNS lesion
where it induces SC dedifferentiation, the production of
neurotrophic and axon survival factors such as GDNF and
Artemin, and myelin clearance by SC myelinophagy5–8. Other
myelination inhibitors including Sox2, Pax3, Notch, Id2 are also
re-expressed in SCs after lesion and are thought to participate in
the SC dedifferentiation process4. Once converted into repair
cells, SCs proliferate and migrate along damaged axons to
organize into bands of Bungner that stimulate axonal regrowth
and guide axons back to their former peripheral target. When
axons have regrown, SCs downregulate myelination inhibitors
and upregulate Krox20 to induce remyelination together with the
major transcription factor of SC differentiation Sox10 (ref. 9). In
contrast to Krox20, the intermediate inducer of SC differentiation
Oct6 is upregulated after lesion and downregulated as SCs
redifferentiate10–12. Oct6 is a key transcription factor for PNS
development and regeneration, allowing timely myelination and
remyelination by inducing Krox20 expression13–15, but needs to
be downregulated for myelination to proceed16. Oct6 thus
importantly participates in triggering the SC differentiation
programme, but also maintains SCs in a pre-myelinating stage.
In summary, SC plasticity after lesion requires dynamic
regulation of several sets of transcription factors, some inducing
SC dedifferentiation or conversion into repair cells, and some
triggering SC redifferentiation and remyelination. Mechanisms
controlling the regulation of these transcription factors are
partially understood. In this study, we set out to elucidate
the mechanisms controlling SC conversion into repair cells
and redifferentiation after lesion with a focus on chromatin-
remodelling events.
We previously showed that the chromatin-remodelling
enzymes histone deacetylase (HDAC)1 and HDAC2 are essential
for the speciﬁcation of neural crest cells into peripheral glia17, for
SC survival and myelination during postnatal development18
(also shown by Chen et al.19), and for the maintenance of PNS
integrity in adults20. While histone acetyltransferases (HATs) add
acetyl groups to histone tails, HDACs remove these acetyl groups.
Because acetyl groups neutralize the positive charges of histones,
histone acetylation loosens the attraction of negatively charged
DNA to histones and thus leads to a more relaxed chromatin
structure. In contrast, HDACs allow histones to recover their
positive charges, which leads to their tight interaction with DNA,
and thus to a more compacted chromatin structure. Because
chromatin compaction limits the access for the transcriptional
machinery to DNA, HDACs have commonly been thought to act
as transcriptional repressors21. However, an increasing number of
studies from independent groups reveal that HDACs can also
participate in transcriptional activation22–24. Furthermore,
HDACs can deacetylate non-histone targets to modify their
activity25. Among those, several transcription factors have been
described. HDACs are thus very potent transcriptional regulators
and their action is highly dependent on their binding partners.
Indeed, HDACs cannot bind chromatin directly, but needs
to associate with DNA-binding proteins to regulate gene
transcription. HDACs are known to belong to different
chromatin-remodelling complexes, which often also comprise
other chromatin-remodelling enzymes such as histone
methyltransferases (HMTs) and demethylases (HDMs)26. In
this study, we show that HDAC2 interacts with the
transcription factor Sox10 and recruits histone H3 lysine
9 (H3K9) HDMs to form a multifunctional protein complex
that de-represses the Sox10 target genes Oct6 and Krox20 to allow
their subsequent activation at different time points of the
regeneration process after lesion. Interestingly, inactivating this
mechanism results in earlier conversion into repair SCs after
lesion and faster regeneration, but impairs remyelination.
Results
HDAC1/2 slow down axonal regrowth but promote remyelination.
There are eighteen known mammalian HDACs, subdivided into
four different classes, based on their structure. HDAC1 and
HDAC2 (HDAC1/2) are two highly homologous nuclear class I
HDACs that can efﬁciently compensate for the loss of each
other17–20. Here, we found that HDAC1/2 were robustly
regulated after sciatic nerve crush lesion in adult mice. HDAC2
was upregulated at 1 day post lesion (dpl) and remained highly
expressed in SCs until completion of the regeneration process
(Fig. 1a,b). Interestingly, HDAC2 was SUMOylated in adult
nerves (Fig. 1c) and SUMOylation was increased after lesion
(Fig. 1a), suggesting modulation of HDAC2 activity, binding
partners and/or stability27 after lesion. HDAC1 was also
upregulated in SCs, but later, starting from 3 dpl (Fig. 1a,b).
HDAC1/2 upregulation and HDAC2 SUMOylation suggested
important functions of these HDACs after lesion. To identify
these potential functions and avoid compensatory mechanisms
between HDAC1 and HDAC2, we ablated both HDACs in adult
SCs by crossing tamoxifen-inducible P0CreERT2 (ref. 28) with
ﬂoxed Hdac1/Hdac2 mice29. We lesioned sciatic nerves of double
homozygous knockout mice (dKO) and their controls at 7 days
post tamoxifen injections, when HDAC1/2 are efﬁciently lost20,
including the SUMOylated form of HDAC2 (Supplementary
Fig. 1). We analysed lesioned sciatic nerves at different
time points after lesion and also unlesioned contralateral sciatic
nerves as internal control for each mouse. We found by
bromodeoxyuridine (BrDU) incorporation that proliferation
was induced earlier after lesion in dKO compared with controls
nerves (Fig. 2a), while we did not detect BrDU-positive cells in
contralateral dKO or control nerves (Supplementary Fig. 2a).
At 3dpl, all BrDU-positive cells were negative for the macrophage
marker F4/80 (Supplementary Fig. 2b), indicating that
proliferating cells were most likely SCs at this time point.
Earlier proliferation suggested earlier SC conversion into repair
cells in the absence of HDAC1/2. Consistently, demyelination
occurred earlier in dKO nerves, as shown by a decreased
percentage of intact myelin rings at 5 dpl (Fig. 2b). Repair SCs
promote axonal regrowth1–3,30. Indeed, at 3 dpl axons had
regrown in average four times longer in dKO compared with
controls (Fig. 2c), as shown by whole-nerve Neuroﬁlament
immunoﬂuorescence analyses. High magniﬁcations delineated
by six coloured boxes at comparable distances to the lesion site
in control and dKO nerves showed in control nerves a
Neuroﬁlament signal of low intensity or fragmented starting
from the second magniﬁcation closest to the lesion site (red box),
whereas Neuroﬁlament signal in dKO nerves remained mostly
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uninterrupted and at high intensity all along the imaged axons
(Fig. 2c). In addition, the marker of axonal regrowth growth-
associated protein 43 (GAP-43) was strongly increased in dKO
compared with control nerves at 3 and 5 dpl (Fig. 2d). Axonal
outgrowth was also increased by three to four times at 5 dpl
(Fig. 2e), as shown by an increased number of axonal sprouts
detected by electron microscopy. We next analysed control and
dKO nerves at 1 month post lesion (mpl) to identify potential
remyelination defects due to HDAC1/2 loss. We found that
remyelinating sheaths were thinner in dKO, as measured by a
higher g ratio (myelin diameter/(axonþmyelin) diameter)
compared to controls (Fig. 2f). These data indicate that
HDAC1/2 slow down demyelination and axonal regrowth after
lesion, but promote remyelination.
HDAC1/2 deletion delays Oct6 but enhances cJun upregulation.
To understand the molecular mechanisms responsible for
HDAC1/2 functions in delaying demyelination and axonal
regrowth after lesion, we ﬁrst determined the precise timing of
transcription factors regulation after lesion. We chose to analyse
expression levels of the myelination inhibitors cJun, Sox2 and
Pax3, because of their previously reported involvement in SC
dedifferentiation process after lesion2,4 and because of the high
quality of available reagents to quantify their expression by
western blot. We also analysed expression levels of the
intermediate inducer of SC differentiation Oct6, because of its
known upregulation in SCs following a PNS lesion10–12.
Consistent with previous ﬁndings10–11, Oct6 was upregulated
very early after lesion, already at 1 dpl, at the mRNA level in
control nerves (Supplementary Fig. 3). Oct6 protein levels
were also upregulated at 1 dpl (Fig. 3a), before myelination
inhibitors including cJun, Pax3 and Sox2 (Fig. 3b–d). Two Oct6
isoforms (one at B42 kDa and a doublet at B50–52 kDa)
were upregulated at 1 dpl and detected after transfection with an
Oct6-expressing construct (Supplementary Fig. 4a). Mass
spectrometry conﬁrmed both Oct6 isoforms detected by the
anti-Oct6 antibody (Supplementary Fig. 4b). The heavier isoform
may result from post-translational modiﬁcations of Oct6.
Alternatively, the lighter isoform may result from cleavage, but
the peptide coverage analysed by mass spectrometry did not allow
to identify a potential cleavage, the most N-terminal and
C-terminal detected peptides being both present in the two
isoforms. Interestingly, while the total protein levels of Oct6
continued to be upregulated after 1 dpl until at least 12 dpl due to
upregulation of the light isoform, the heavier isoform disappeared
at 3 dpl and reappeared starting from 5 dpl. It is possible that
these two Oct6 isoforms have different functions, but more work
is needed to clarify this point. Oct6, which is highly expressed
during development and downregulated in adult SCs (heavier
isoform; ref. 14; Supplementary Fig. 4c), allows timely expression
of the myelination inducer Krox20 during myelination and
remyelination12,13,15. However, Krox20 upregulation after lesion
occurs at a later time point as compared to Oct6 (ref. 9),
suggesting another potential function of Oct6 upregulation at
1 dpl.
In dKO crushed nerves, Oct6 upregulation was delayed and
levels were decreased compared with control crushed nerves
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Figure 1 | HDAC1/2 are robustly upregulated in SCs after lesion. (a) Western blots of HDAC2 and HDAC1 in lysates of crushed (Cr) and contralateral
(Co) nerves of adult mice at 1 dpl (n¼ 5), 3 dpl (n¼ 5), 5 dpl (HDAC2, n¼6; HDAC1, n¼ 7), 12 dpl (HDAC2, n¼ 6; HDAC1, n¼ 8), 30 dpl (HDAC2, n¼ 6;
HDAC1, n¼ 8) and 60 dpl (n¼6), and quantiﬁcation normalized to GAPDH and compared to Co¼ 1, showing HDAC1/2 upregulation after lesion. Of note:
both bands detected by the HDAC2 antibody were quantiﬁed and added together in the graph. (b) Co-immunoﬂuorescence of HDAC2 or HDAC1 (red)
with CD68 (green¼macrophages) and DAPI labelling (blue¼ nuclei, overlay appears pink) at 12 dpl, showing upregulation in SCs (CD68-negative cells
with elongated nuclei, white arrows) of crushed compared to contralateral nerves. Note that macrophages (CD68-positive cells, blue arrowheads) express
variable levels of HDAC1 and HDAC2. Scale bar, 10mm. (c) Denaturing IP of SUMO-1, HDAC2 (H2) or control Flag (ctrl) in unlesioned (no lesion)
adult mouse sciatic nerve lysates, and western blot of HDAC2, showing that the B75 kDa band detected by the HDAC2 antibody corresponds to a
SUMOylated form of HDAC2. HDAC2 and GAPDH western blots on lysates used for IP show the inputs. Representative photos of three independent
experiments are shown. One-tailed (HDAC2, 12 dpl and 60 dpl; HDAC1, 5 dpl) or two-tailed Student’s t-tests, unpaired (HDAC2: 3 dpl) or paired, P values:
*Po0.05, **Po0.01, ***Po0.001. Values, mean; error bars, s.e.m.
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(Fig. 3a,e,f), while Oct6 levels were not affected in contralateral
nerves of dKO compared with control mice, except for a mild
decrease at 12 dpl (Supplementary Fig. 5a). Oct6 protein
(Fig. 3a,e) and mRNA (Fig. 3f) were affected, indicating
impairment at the transcriptional level. In contrast, cJun
upregulation occurred earlier and to a higher level in dKO
compared with control crushed nerves (Fig. 3b,g), while levels
were not affected in contralateral nerves of dKO compared
with control mice (Supplementary Fig. 5b). Consistently, glial cell
line-derived neurotrophic factor (GDNF), a cJun target gene,
was upregulated earlier in dKO crushed nerves already at 3 dpl
compared with control crushed nerves where expression was
detectable later at 5 dpl (Supplementary Fig. 6). As for Pax3 and
Sox2, expression levels remained mostly unaffected (Fig. 3c,d).
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Figure 2 | HDAC1/2 slow down axonal regrowth but promote remyelination. (a) BrdU incorporation (green) and DAPI (blue) identifying earlier induction
of proliferation in dKO compared to control nerves. Scale bar¼ 10mm. Electron micrographs (b,e) and toluidine-blue staining (f) and quantiﬁcation showing
in dKO compared to controls a decreased percentage of intact myelin rings (b, scale bar¼ 10mm) and increased number of axonal sprouts (e, Scale bar,
5 mm) at 5 dpl, and thinner remyelinating sheaths at 1 month post lesion (mpl) (higher g ratio in dKO, (f), Scale bar, 10mm). (c) Z-series projections of
whole-nerve Neuroﬁlament immunoﬂuorescence in control and dKO nerves, brightﬁeld showing lesion site and axonal tracings (acquired using NeuronJ,
Scale bar, 300mm) quantifying axonal regrowth from the lesion site. White arrows, fragmented axons. Coloured boxes, magniﬁcations (Scale bar, 100 mm).
(d) Z-series projections of GAP-43 immunoﬂuorescence (green) and DAPI labelling (blue¼ nuclei) showing strongly increased GAP-43 expression in dKO
compared with control nerves at 3 dpl (20-mm thick cryosections) and 5 dpl (5-mm thick cryosections). Scale bar, 30mm. Note that immunoﬂuorescence
staining of 3 dpl sections was not carried out at the same time as staining of 5 dpl sections, and imaging was also done separately with different exposure
times. Unpaired two-tailed Student’s t-tests, P values: *Po0.05, **Po0.01. Values, mean, error bars, s.e.m. Sample size: n¼ 3 animals per group per time
point for all graphs, electron microscopy and immunoﬂuorescence. (a) Number of cells counted: 334 to 469 per animal at 3 dpl (per genotype: 1,218 for
controls, 1,140 for dKO); 111 to 727 per animal at 5 dpl (per genotype: 1,779 for controls, 1,262 for dKO); 553 to 4,380 per animal at 12 dpl (per genotype:
5,440 for controls, 8,892 for dKO). (b) Number of myelin rings counted: 344 to 469 per animal. (c) Number of tracings: 10 to 25 per nerve. (d) Surface of
nerve ultrathin section counted: 0.026 to 0.03mm2 per animal. (e) 60–70 myelinated axons (randomly chosen) counted per nerve. The g ratio (axon
diameter: axonþmyelin diameter) of both contralateral (0.71 for control and 0.72 for dKO nerves, P value¼0.32: no signiﬁcant difference between control
and dKO) and crushed nerves was measured.
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Figure 3 | Delayed Oct6 and earlier/higher cJun upregulation in dKO. Western blots and quantiﬁcation normalized to GAPDH of (a) Oct6, (b) cJun,
(c) Pax3, and (d) Sox2 in crushed (Cr) and contralateral (Co¼ 1) nerves of control (Ctrl) and dKO, showing delayed Oct6 upregulation and earlier/higher
cJun upregulation in dKO. Of note: the double band atB52 kDa and the lower band atB42 kDa detected by the Oct6 antibody were quantiﬁed and added
together in the graph. Dashed lines: samples run on the same gel, but not on consecutive lanes. In a–d, coloured graphs quantify protein levels in
Cr compared to Co, and grey/white bar graphs quantify protein levels in dKO compared with Ctrl crushed nerves. (e,g) Co-immunoﬂuorescence of Oct6
(red, e) at 5 dpl or of cJun (green, g) at 1 dpl with the macrophage marker F4/80 (green in e, red in g) and DAPI labelling (nuclei) in control and dKO nerves
showing decreased Oct6 and increased cJun levels in SCs of dKO compared with control nerves. White arrows indicate SCs (F4/80-negative cells with
elongated nuclei) and blue arrowheads indicate macrophages (F4/80-positive cells). (f) Oct6 in situ hybridization in control and dKO nerves at 5 dpl
showing decreased Oct6 transcript levels in dKO. Sample size: (a–d) 5 animals per group for 1 dpl, 2 dpl and 3 dpl, and 6 or 9 animals per group for 5 dpl
and 12 dpl; (e–g) 3 animals per group. One-tailed (grey asterisk; blue/red asterisks: Control Oct6 at 5 dpl, Control cJun at 5 dpl, dKO cJun at 12 dpl, Control
Pax3 at 2 dpl, Control Sox2 at 3 dpl and 5 dpl) or two-tailed (black asterisks; blue/red asterisks: other values) Student’s t-tests, unpaired (bar graphs, and
cJun at 2 dpl in coloured graph) or paired (coloured graphs, except for cJun at 2 dpl), P values: *Po0.05, **Po0.01. Values, mean; error bars, s.e.m. Scale
bar, 10 mm.
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cJun is a major inducer of SC dedifferentiation and conversion
into repair SCs, critically promotes axonal regrowth and survival,
is required for functional recovery after PNS lesion, and is
sufﬁcient, when expression is enforced using adenoviral vectors,
to restore regeneration kinetics after crush in nerves of Wlds slow
regenerating mutant mice7,8. Thus, earlier SC conversion into
repair cells and faster axonal regrowth in dKO is due at least
partly to earlier and higher cJun upregulation compared with
controls.
Reduced Oct6 levels allow earlier conversion into repair SCs.
To analyse a potential causal relationship between delayed Oct6
and earlier/higher cJun upregulation, we used primary rat SCs
(RSCs) and a dedifferentiation culture protocol (ref. 31;
Supplementary Fig. 7). Oct6 downregulation by shRNA during
RSC dedifferentiation increased cJun upregulation (Fig. 4a) and
SC proliferation (Fig. 4b), but did not signiﬁcantly affect Sox2 or
Pax3 levels (Supplementary Fig. 8). Consistently, in Oct6 delta
(D¼ deleted) SC enhancer (SCE) mice, where deletion of the SCE
prevents Oct6 upregulation after lesion (ref. 12; Fig. 4c), cJun was
upregulated earlier than in controls already at 1 dpl (Fig. 4d), and
demyelination was increased at 5 dpl compared with controls
(Fig. 4e, decreased percentage of intact myelin rings in Oct6 DSCE
nerves), such as in dKO (Figs 3b and 2b, respectively). Also,
consistent with dKO, axons had regrown signiﬁcantly longer at
3 dpl (Fig. 4f). These data indicate that earlier cJun upregulation
and conversion into repair SCs, and faster axonal regrowth in
dKO mice after lesion are due at least partly to reduced Oct6
levels.
HDAC1/2 deletion leads to reduced Krox20 and P0 expression.
We next analysed expression levels of promyelinating factors and
myelin proteins at the redifferentiation and remyelination stages.
At 12 dpl, Krox20 was upregulated (Fig. 5a) and remyelination
started (data not shown). We found that protein (Fig. 5b,c) and
mRNA (Fig. 5d) levels of Krox20 at 12 dpl were strongly reduced
in dKO compared with controls, while expression levels of Sox10,
the other major inducer of SC myelination, were not affected by
the loss of HDAC1/2 (Fig. 5b). Similar to Krox20, expression
levels of P0 mRNA (Fig. 5e) and protein (Fig. 5f) were strongly
reduced at 1 mpl in dKO compared with control nerves. Krox20
is required for myelin formation and maintenance and for
postnatal expression of P0 (refs 32,33), and P0 is an essential
component of PNS myelin34. The thinner remyelination in dKO
compared with control nerves is thus due at least partly to the
failure of dKO SCs to upregulate Krox20 and P0 during
redifferentiation and remyelination.
HDAC2 recruits JMJD2C and KDM3A to Oct6 and Krox20.
We next aimed at elucidating HDAC1/2-dependent mechanisms
controlling Oct6 upregulation after lesion. The Oct6 SCE contains
two functionally interdependent conserved modules HR1 and
HR2 sufﬁcient to activate Oct6 developmental expression35.
Exogenous DNA transiently applied to cells is present in
nucleosomal DNA at about the same levels as endogenous
DNA36. Therefore, we carried out luciferase gene reporter assays
in RSCs to analyse whether HDAC1/2 modulate the Oct6 SCE
activity during dedifferentiation. HDAC1 or HDAC2
overexpression increased the activity of the full Oct6 SCE and
the DHR1 SCE, but not of the DHR2 SCE (Fig. 6a), suggesting
that HDAC1/2 activate the Oct6 SCE HR2. By chromatin
immunoprecipitations (ChIP), we found increased HDAC2
enrichment at the HR2 at 1 dpl compared with unlesioned (no
lesion) nerves (Fig. 6b), while HDAC1 was not bound
(Supplementary Fig. 9). Consistently, HDAC2 overexpression in
primary RSCs cultured under dedifferentiating conditions
increased Oct6 mRNA levels (Fig. 6c).
HDACs have been described to act within multiprotein
complexes that often contain HMTs or HDMs26. To
understand the mechanism by which HDAC2 activates the Oct6
SCE HR2, we tested the potential effects of de-repressive K
HDMs on Oct6 upregulation after lesion. Repressive K histone
methylation marks are located on H3K9, H3K27 and H4K20.
Among all known de-repressive K HDMs (data not shown),
JMJD2C (H3K9me3 HDM) or KDM3A (H3K9me2/1 HDM)
overexpression increased Oct6 mRNA levels in RSCs (Fig. 6c) and
the activation of the full Oct6 SCE and the DHR1 SCE, but not of
the DHR2 SCE (Fig. 6d), similar to the effect of HDAC2
overexpression. HDAC1/2 inhibition by Mocetinostat prevented
JMJD2C- and KDM3A-mediated Oct6 SCE activation (Fig. 6d),
indicating that this activation is HDAC1/2-dependent. To test the
relevance of these ﬁndings in vivo, we ﬁrst analysed the
endogenous expression of JMJD2C and KDM3A in adult nerves
after lesion and in primary RSCs cultured under dedifferentiation
conditions. Compatible with potential functions in regulating
Oct6 expression after lesion, JMJD2C and KDM3A were
endogenously expressed in SC nuclear and cytoplasmic
compartments after nerve lesion (Supplementary Fig. 10a,b)
and also in dedifferentiated RSCs in culture (Supplementary
Fig. 11a,b). Interestingly, they were both upregulated at 5 dpl
(Supplementary Fig. 10a,b). By ChIP, we show in control nerves
that JMJD2C is recruited to the HR2 at 1 dpl (Fig. 6e;
Supplementary Fig. 12a) and KDM3A enriched at the HR2 in
both unlesioned nerves and at 1 dpl (Fig. 6e; Supplementary
Fig. 12b). In contrast, neither JMJD2C nor KDM3A were bound
to the HR2 in dKO nerves (Fig. 6e). Consistently, H3K9me3/2
repressive marks were reduced in this region in control nerves at
1 dpl compared with unlesioned nerves (Fig. 6f), whereas in dKO
H3K9me3 marks were increased (Fig. 6g). Interestingly,
H3K9me2 marks were strongly reduced in dKO nerves
(Fig. 6g), possibly due to some extent to impaired H3K9me3
demethylation. Taken together, these data demonstrate that
HDAC2 allows JMJD2C and KDM3A recruitment to the Oct6
SCE HR2 for de-repression by H3K9 demethylation early after
lesion.
We found strongly reduced Krox20 levels in dKO nerves at 12
dpl (Fig. 5b–d), at the time point where Krox20 is upregulated in
control nerves to induce remyelination (Fig. 5a). Reduced Krox20
expression in the absence of HDAC1/2 may be partly due to
delayed Oct6 upregulation after lesion. However, Oct6 levels are
not signiﬁcantly reduced at 12 dpl in dKO compared with control
nerves. We thus asked whether HDAC1/2 directly regulate
Krox20 expression after lesion. Indeed, at 12 dpl HDAC2,
JMJD2C and KDM3A were recruited to the Krox20 MSE
(myelinating Schwann cell element15; Fig. 6h), an essential
enhancer for Krox20 expression in postnatal SCs. Consistently,
H3K9me3/2 repressive methylation marks in this region were
decreased at 12 dpl (Fig. 6h). Similar to their effect on the Oct6
SCE HR2, KDM3A or JMJD2C overexpression activated the
Krox20 MSE in an HDAC1/2-dependent manner in RSCs
cultured under redifferentiating conditions (Fig. 6i).
These data suggest that HDAC2, JMJD2C and KDM3A
subsequently de-repress the Oct6 SCE HR2 and the Krox20
MSE after lesion to allow upregulation of Oct6 and Krox20.
Oct6 and Krox20 activation by Sox10 depends on HDAC1/2.
The Oct6 SCE and Krox20 MSE are known targets of Sox10, a
major transcription factor of SC differentiation37, and we
previously showed that Sox10 requires HDAC1/2 to upregulate
Pax3 and P0 during SC speciﬁcation17, Sox10 itself and Krox20
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during postnatal development18. We thus hypothesized that
Sox10 coordinates the activation of the Oct6 SCE and Krox20
MSE after lesion with HDAC2-, JMJD2C- and KDM3A-mediated
de-repression of these targets. Indeed, Sox10 recruitment to the
Oct6 SCE HR2 and Krox20 MSE was increased at 1 and 12 dpl,
respectively, compared with unlesioned nerves (Fig. 7a,b).
In RSCs cultured under dedifferentiating conditions, Sox10
overexpression increased the DHR1, but decreased the DHR2
Oct6 SCE activation (Fig. 7c), suggesting HR1 repression and
HR2 activation by Sox10 during dedifferentiation. Sox10 also
increased Krox20 MSE activation in redifferentiating conditions
(Fig. 7d). Sox10-induced activation of the HR2 (DHR1 construct)
and the Krox20 MSE was respectively fully and partly dependent
on HDAC1/2 activity (Fig. 7c,d).
Protein complex activating Sox10 target genes after lesion.
Consistent with HDAC1/2 known functions on histones, we
found increased levels of acetylated histone H3 in dKO nerves at
the Oct6 SCE HR2 at 1 dpl and at the Krox20 MSE at 12 dpl
(Supplementary Fig. 13a,b), despite impaired Oct6 and Krox20
transcription. This indicates that histone acetylation or
hyperacetylation in gene enhancers does not always correlate
with transcriptional activation and supports the hypothesis that
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this may hamper the activation of some genes21–23 or their
de-repression. HDAC2 SUMOylation at lysine 462 has been
shown to be required for HDAC2 activity and protein–protein
interaction38,39. We thus generated an HDAC2K462R mutant
and tested whether this mutation affects HDAC2 ability to
activate the Oct6 SCE and Krox20 MSE. Indeed, HDAC2K462R
overexpression strongly reduced the Oct6 SCE and Krox20 MSE
activation (Supplementary Fig. 14), indicating that overexpressed
HDAC2K462R overrode endogenous HDAC2 effects and that
SUMOylation at lysine 462 is critical for HDAC2-dependent
activation of these targets. We hypothesized that HDAC2,
JMJD2C, KDM3A and Sox10 form a multifunctional protein
complex that de-represses Sox10 targets and subsequently
activates them. Indeed, SUMOylated HDAC2, JMJD2C,
KDM3A and Sox10 interacted in unlesioned adult nerves
(Fig. 8a–c), possibly to keep active Sox10-target genes such as
P0 for the maintenance of PNS integrity20. This complex was also
assembled at 1 dpl and 12 dpl (Fig. 8a–c). Taken together,
our data indicate that this complex is sequentially recruited
to the Oct6 SCE HR2 at 1 dpl and to the Krox20 MSE at 12 dpl
to de-repress and reactivate the transcription of these genes
after lesion.
HDAC1/2 inhibitor treatment accelerates functional recovery.
Faster axonal regrowth in dKO compared with controls
supported a potential beneﬁt of inhibiting HDAC1/2 during the
ﬁrst regeneration step after lesion. We thus treated mice with
the HDAC1/2 inhibitor Mocetinostat for 3 or 5 days or with
vehicle after lesion, to test whether this treatment accelerates
regeneration kinetics. Mocetinostat is currently in Phase 2 clinical
trials for the treatment of various cancers and did not induce
detectable adverse effects during or after the treatments we
carried out in mice. Mass spectrometry analyses on the nerves of
mice treated with Mocetinostat revealed increased abundance of
histone peptides compared with vehicle, after immunoprecipita-
tion with an anti-acetyl-lysine antibody (Supplementary Fig. 15),
suggesting efﬁciency of HDAC1/2 inhibition. Of note, HDAC1/2
are ubiquitously expressed, thus HDAC1/2 inhibitor treatment
can potentially impact any cell type. A large majority (B85%) of
nuclei present in the sciatic nerve at 1 dpl belongs to the Schwann
cell lineage, while the remaining fraction can be inferred
to endoneurial ﬁbroblasts (B10%) and a few macrophages.
Therefore, increased abundance of histone peptides and peptides
of other nuclear proteins is likely due in large majority to
HDAC1/2 inhibition in SCs; however, the effect of HDAC1/2
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inhibition in ﬁbroblasts and macrophages may contribute to
some extent to the observed results. Three-day Mocetinostat-
treated mice showed faster motor function and toe sensitivity
recovery at 10 dpl (Fig. 9a,b), and at 18 dpl both Mocetinostat-
treated groups had recovered toe sensitivity faster than vehicle-
treated mice (Fig. 9b). Similar to dKO nerves, Oct6 was decreased
and cJun increased at 1 dpl (Fig. 9c) and axons had regrown faster
at 3 dpl (Supplementary Fig. 16) in nerves of Mocetinostat-
treated mice compared with the vehicle group. Interestingly, this
short-term Mocetinostat treatment resulted in improved regen-
eration at the morphological level: the density of sorted axons
(mostly remyelinated) and of Remak bundle axons was increased
in both Mocetinostat-treated groups compared to vehicle at 30
dpl (Fig. 9d). In addition, myelin thickness was subtly but sig-
niﬁcantly increased in nerves of 3-day Mocetinostat-treated mice
as shown by a lower g ratio compared with the vehicle group
(Fig. 9d), suggesting together with faster motor function recovery
(Fig. 9a) that a 3-day treatment is optimal to improve overall
regeneration efﬁciency.
Discussion
After a PNS lesion, SCs not only dedifferentiate, but they also
activate a repair programme that fosters axonal regeneration. The
SC stage after lesion is thus distinct from the immature SC stage.
This is why the concept of conversion into repair SCs or
transdifferentiation has been recently established to provide a
speciﬁc term corresponding to the cell cycle changes that SCs
undergo after lesion. Repair SCs then redifferentiate to rebuild
myelin of regenerated axons. These dynamic changes are
associated with the regulation of several transcription factors
that are thought or demonstrated to induce the different phases of
the regeneration process in SCs, although the mechanisms
controlling these regulations are not fully understood. In this
study, we investigated the potential involvement of HDAC1 and
HDAC2 in these mechanisms.
Our initial ﬁndings identifying a robust upregulation of
HDAC1 and HDAC2 in SCs after lesion suggested important
functions of these HDACs during the regeneration process.
Indeed, ablation of HDAC1/2 in adult SCs led to impaired
remyelination after lesion. This was consistent with previous
studies of our group18 and others19 demonstrating critical
functions of HDAC1/2 in developmental myelination of the
PNS, by the control of Sox10, Krox20 and P0 transcription in
postnatal SCs. In adult SCs after lesion, Sox10 levels were not
affected by the ablation of HDAC1/2, but Krox20 re-expression
was strongly reduced at the remyelination stage. In addition,
we found that HDAC1/2—primarily HDAC2—also control the
early phase of Oct6 upregulation after lesion, starting at 1 day
post lesion. Considering the functions of HDAC2 and Oct6
in inducing SC differentiation, such an early upregulation of
HDAC2 and Oct6 appeared counterintuitive. However, early
upregulation of Oct6 in SCs after lesion conﬁrmed previously
reported observations10,11. Oct6 is critical for timely induction
of Krox20 expression, but Krox20 is re-expressed to drive
remyelination at around 12 dpl, at a much later stage as compared
to Oct6 upregulation. This suggests that Oct6 is not only an
inducer of Krox20 expression and may have other functions
during regeneration. In support of this hypothesis, Oct6 is
known to maintain SCs in a pre-myelinating stage10,40,
Oct6 SCE HR2 Oct6 ΔHR1 (3)
Fo
ld
 e
nr
ich
m
en
t
Fo
ld
 e
nr
ich
m
en
t
Lu
ci
fe
ra
se
 a
ct
ivi
ty
Lu
ci
fe
ra
se
 a
ct
ivi
ty
Lu
ci
fe
ra
se
 a
ct
ivi
ty30
20
10
0
5
4
3
2
1
0
GFPNo lesion No lesion 1 dpl
Sox10Neg
1 dpl
Sox10Neg
No lesion No lesion 1 dpl1 dpl
GFP GFP Sox10Sox10Sox10
GFP GFP Sox10Sox10
Oct6 SCE
(full)
Oct6
ΔHR1 (3)
Oct6 ΔHR2
GFP GFP Sox10Sox10
Vehicle
Vehicle
HDAC1/2
inhibitor
HDAC1/2 inhibitor
5
4
3
2
1
0
5
6
4
3
2
1
0
3
2.5
2
1.5
1
0.5
0
Krox20 MSEKrox20 MSE
++***
*
*
*
*
**
+
db
a c
Figure 7 | Oct6 and Krox20 activation by Sox10 depends on HDAC1/2. Chromatin immunoprecipitation of Sox10 and GFP (Neg¼ 1) in (a) unlesioned
(no lesion) nerves or at 1 dpl on the Oct6 SCE HR2, or in (b) unlesioned nerves or at 12 dpl on the Krox20 MSE. Relative luciferase activity of (c) the
full Oct6 SCE, the DHR1 (construct #3; ref. 35) and DHR2 SCE, or of (d) the Krox20 MSE, in primary RSCs transfected with GFP (¼ 1) or Sox10 expression
constructs and cultured under dedifferentiating (c) or redifferentiating (d) conditions for 1 day, in the presence of Mocetinostat (HDAC1/2 inhibitor) or its
vehicle (c,d). One-tailed (grey asterisk or cross) or two-tailed (black asterisks or crosses) Student’s t-tests, unpaired (a,b;c,d: HDAC1/2 inhibitor compared
with Vehicle) or paired (c,d: Sox10 compared with GFP), P values: *Po0.05, þPo0.05; **Po0.01, þþPo0.01; and ***Po0.001. Values, mean; error bars,
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its downregulation being necessary for myelination to proceed16.
However, although the underlying molecular mechanisms remain
to be elucidated, our ﬁndings indicate that early upregulation of
Oct6 after lesion transiently counteracts the upregulation of cJun,
a key inducer of SC dedifferentiation and conversion into repair
cells. This may indicate that early Oct6 upregulation after lesion
triggers the very start of the SC redifferentiation programme and
act as a priming event for later remyelination. Alternatively, early
Oct6 upregulation after lesion may be the result of an innate SC
reaction to injury attempting to maintain the myelinating state.
This would somewhat resemble the transient upregulation of
myelin proteins observed in oligodendrocytes, the myelinating
glia of the CNS, in response to a CNS injury4,41. In any case,
we show here that early upregulation of Oct6 after lesion is not
necessary and even acts as a brake for the regeneration process.
Indeed, our study demonstrates that the innate SC response to
injury upregulating HDAC2 early after lesion is not optimal for
regeneration speed, this speed being substantially increased by
short-term inhibition of HDAC1/2 after lesion. This prevents
early Oct6 upregulation and results in earlier cJun upregulation
and faster recovery of motor and sensory functions correlating
with faster axonal outgrowth and increased density of regenerated
axons. Interestingly, the shortest HDAC1/2 inhibitor treatment
we carried out (3-day Mocetinostat) also subtly increased myelin
thickness at 1 mpl, suggesting that faster axon regeneration may
allow earlier remyelination. However, this is speculative and
needs to be further tested. A longer Mocetinostat treatment of
5 days also led to increased density of regenerated axons at 1 mpl
and to faster sensory function recovery, but less fast than the
3-day treatment, and did not lead to faster motor function
recovery, nor to increased myelin thickness. We hypothesize that
a longer treatment with the HDAC1/2 inhibitor may slow down
remyelination, but this also needs to be further tested.
Besides the potential medical applications of our ﬁndings,
we were very interested in understanding the molecular basis
of HDAC1/2-mediated activation of Oct6 expression. Oct6
transcription in SCs depends on the activation of the SCE,
a SC-speciﬁc enhancer located B10 kb downstream of Oct6
transcriptional start site. The SCE comprises two functionally
interdependent conserved modules called HR1 and HR2 that
contain Sox10 binding sites. We found that overexpression of
HDAC1 or HDAC2 activates the Oct6 SCE HR2 in primary RSCs
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blots on lysates used for IP show the inputs (in a, only one input for no lesion IP KDM3A and ctrl that were done on the same lysate divided by two).
Sample size: each IP was done three times, using nerves of three different animals. One nerve was used per IP.
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cultured under dedifferentiating conditions. However, only
HDAC2 was recruited to the HR2 at 1 dpl in mouse nerves,
correlating with its early upregulation after lesion, whereas
HDAC1 is upregulated later. HDAC1/2 are known to belong to
various chromatin-remodelling complexes that often include
other chromatin-remodelling enzymes, such as HMTs or HDMs.
Most of these complexes have been reported to silence rather than
activate gene transcription, thus we set out to identify novel
protein complexes that can activate transcription.
We found that the H3K9 HDMs JMJD2C and KDM3A are
recruited/enriched at the Oct6 SCE HR2 in an HDAC1/2-
dependent manner at 1 dpl to demethylate this region of the SCE
and allow its de-repression by H3K9 demethylation. The same
HDMs were also recruited to the Krox20 MSE at 12 dpl when
Krox20 is upregulated to induce remyelination. The Oct6 SCE
and the Krox20 MSE are direct targets of the transcription factor
Sox10, and we previously found that HDAC2 interacts with
Sox10 to activate different Sox10 target genes during SC
development. Here we identify the assembly of a multifunctional
protein complex containing HDAC2, JMJD2C, KDM3A and
Sox10 in adult nerves, with the likely function of keeping active
Sox10 target genes necessary for the maintenance of PNS
integrity, such as P0 (ref. 20). After lesion, this complex is
subsequently recruited to the Oct6 SCE HR2 and the Krox20MSE
for their de-repression and activation.
Interestingly, we show that HDAC2 is SUMOylated in adult
nerves and that SUMOylation is increased after lesion. In
mammalian cells, HDAC2 is known to be SUMOylated by small
ubiquitin-related modiﬁer (SUMO)-1 (ref. 38). SUMOylation
is achieved by an enzymatic machinery consisting of an
E1-activating enzyme (SAE1 or SAE2), the SUMO E2-conjugase
Ubc9 and a SUMO E3-ligase (15 mammalian enzymes currently
known). This machinery catalyses the covalent attachment of
SUMO to lysine residues that can be removed by SUMO-speciﬁc
proteases (seven known enzymes SENP-1 to SENP-7).
SUMOylation is known to modify the activity, binding partners
and/or stability of proteins27. HDAC2 SUMOylation at K462 has
been previously demonstrated to be necessary for HDAC2 activity
and protein–protein interaction, in the context of HDAC2
binding and deacetylation of p53 (ref. 38). Consistent with this,
we show here that SUMOylated HDAC2 is the detectable form of
HDAC2 interacting with JMJD2C, KDM3A and Sox10 in adult
sciatic nerves, and overexpression of the SUMOylation-deﬁcient
HDAC2 mutant HDAC2K462R decreases the activity of the Oct6
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Figure 9 | HDAC1/2 inhibitor treatment accelerates functional recovery. Quantiﬁcation of motor function recovery by Rotarod test at 4 and 10 dpl
(a) and of sensory function recovery by toe pinch test at 10, 16, 18 and 29 dpl (b) in vehicle, 3-day or 5-day Mocetinostat-treated mice after sciatic nerve
lesion. (c) Western blot of Oct6 and cJun and quantiﬁcation normalized to GAPDH showing reduced Oct6 and increased cJun levels in nerves of mice
treated with Mocetinostat (Moc.) for 1 day after lesion compared to vehicle (Veh.). (d) Electron micrographs of nerve ultrathin sections from vehicle, 3-day
and 5-day Mocetinostat-treated mice and quantiﬁcation showing increased density of sorted (mostly myelinated) axons and Remak bundle axons in both
Mocetinostat-treated groups and increased myelin thickness at 30 dpl in the 3-day Mocetinostat-treated group, compared with vehicle (Veh.). Scale bar,
5 mm. One-tailed (grey asterisks) or two-tailed (black asterisks) unpaired Student’s t-tests, P values: *Po0.05, **Po0.01, ***Po0.001. Values, mean; error
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SCE HR2 and the Krox20 MSE, thus acting as a dominant-
negative HDAC2 mutant. These results thus identify a critical
function of SUMOylation for HDAC2 activity on its targets after
lesion.
What remains to be elucidated is the direct deacetylation target
of HDAC1/2 that allows the recruitment of JMJD2C and KDM3A
to the Oct6 SCE HR2 and the Krox20 MSE. As expected from the
known function of HDAC1/2 on histones, we found hyperace-
tylation of histone H3 at the Oct6 SCE HR2 and the Krox20 MSE
at 1 and 12 dpl, respectively, in dKO nerves, despite impaired
transcription of Oct6 and Krox20 at these time points. These data
indicate that hyperacetylation of histones in gene regulatory
regions does not always correlate with increased transcriptional
activation. This is consistent with previous studies showing that
HATs and HDACs are simultaneously recruited to active genes to
provide an appropriate level of histone acetylation for gene
elongation, and to reset chromatin to maintain genes in an active
state21,22. Further investigations are needed to identify whether
histone deacetylation or deacetylation of another protein by
HDAC1/2 critically regulates JMJD2C and KDM3A recruitment
to target genes after lesion.
In summary, we demonstrate that, after a PNS lesion,
SUMOylated HDAC2, JMJD2C and KDM3A collaborate in adult
SCs to sequentially de-repress Oct6 and Krox20, two Sox10
target genes critical for SC development and redifferentiation
programme after lesion (mechanism summarized in Fig. 10). This
mechanism acts as a brake for SC conversion into repair cells and
axonal regrowth, but drives remyelination. This brake can be
released by short-term treatment with an HDAC1/2 inhibitor
after lesion, thereby accelerating regeneration of peripheral nerves
and identifying a new therapeutic strategy for the improvement of
peripheral nerve regeneration after lesion.
Methods
Statistical analyses. For each data set presented, experiments were performed at
least three times (exact n indicated in each ﬁgure legend) and P values were
calculated using two-tailed (black asterisks and crosses in the ﬁgures) or one-tailed
(grey asterisks or crosses in the ﬁgures) Student’s t-tests. P values: *Po0.05,
þPo0.05; **Po0.01, þþPo0.01; and ***Po0.001, þþþPo0.001. For data
sets obtained using animals or their tissues, three to nine animals were used per
group and tissues of each animal were processed independently. For data sets
obtained using cells, three to 12 independent experiments were conducted and
analysed. For animal experiments, sample size was determined by the minimal
number of animals required to obtain statistically signiﬁcant results, and increased
in some cases to improve conﬁdence in the results obtained (n¼ 3–5 for
microscopy, n¼ 5–8 for western blot analyses, n¼ 8–9 for behavioural analyses).
No animal or sample was excluded from the analysis.
Animals. Tamoxifen-inducible Schwann cell-speciﬁc HDAC1/2 knockout mice
(dKO20) and Oct6 DSCE mice12 have been previously described. To temporally
induce gene ablation in dKO adult mice (B30 g body weight), we administered
2mg tamoxifen intraperitoneally (i.p.) daily for 5 days. As control mice, we used
tamoxifen-injected littermate mice of the same sex whenever possible, and at least
tamoxifen-injected age-matched mice of the same sex with similar genetic
background (from breedings of the same mouse lines). Surgery: we used Isoﬂurane
(3% for induction, 1.5–2% for narcosis during operation) for anaesthesia. For
analgesia, 0.1mg kg 1 per body weight buprenorphine (Temgesic; Essex Chemie)
was administered by i.p. injection 1 h before nerve lesion and after the operation
every 12 h during 3 days. The ﬁeld of operation was cleaned and disinfected. An
incision was made at the height of the hip and the sciatic nerve was exposed on one
side. The nerve was crushed (5 10 s with crush forceps: Ref. FST 00632-11). The
wound was closed using Histoacryl Tissue Glue (BBraun). After the operation,
mice were wrapped in paper towels and placed on a warming pad until recovery
from anaesthesia. When necessary, Mocetinostat (HDAC1/2 inhibitor) or its
vehicle was injected in the pelvic cavity at 10mg kg 1 after wound closing and
mice were sacriﬁced either 24 h later or treated again once a day for 2 days (3-day
treated) or 4 days (5-day treated) for functional recovery experiments. In some
cases, BrDU (100mg kg 1 body weight) was injected i.p. two hours before killing
to mark proliferating cells. Before collection of sciatic nerves, mice were killed by a
lethal i.p. injection of 150mg kg 1 Pentobarbital (Esconarkon; Streuli Pharma
AG). Male and female mice of mixed strains and between 3 and 4 months of age
were used. No randomization method was used, but experimenters were blinded to
the experimental group (genotype, treatment) and received only the animal
number given at birth by the animal caretaker. Animal use was approved by the
Veterinary ofﬁce of the Canton of Fribourg.
Functional recovery experiments. Mice were placed three times on the Rotarod
apparatus at a ﬁxed speed of 15 r.p.m. to test balance and motor coordination, at
4 and 10 days post lesion. The duration of each trial was limited to 300 s, and trials
were separated by a 30min recovery period. Latency to fall from the rotating beam
was recorded and the average of the three trials was used for quantiﬁcation.
Recovery of sensory function was tested at 4, 10, 16, 18 and 29 dpl by toe pinch test:
each toe of the rear foot on the right side (lesioned side) was pinched with equal
pressure applied by the same experimenter using ﬂat tip forceps. Immediate
withdrawal was recorded as functional sensitivity of the pinched toe. In case no toe
exhibited sensitivity, the same test was applied to toes of the contralateral side
(uninjured side), which always resulted in immediate withdrawal. All tests were
carried out with the same experimental animals (16 Mocetinostat-treated mice:
8 for the 3-day treatment group and 8 for the 5-day treatment group, and 9
vehicle-treated mice). All mice were between 3 and 4 months old. The
experimenter was blinded regarding the treatment that mice received.
Constructs. Expression constructs: pBJ5 HDAC1 expression construct (kind gift
from S. Schreiber), pME1 8 S HDAC2 expression construct (kind gift from E. Seto),
Sox10 expression construct (kind gift from M. Wegner), p3xFlag-CMV-JMJD2C
(kind gift from Adolfo Saiardi), pcDNA4-FLAG-Jhdm2a (ref. 42; ¼KDM3A,
gift from Toshinobu Nakamura & Toru Nakano, Addgene plasmid #38136).
HDAC2K462R was generated by site-directed mutagenesis, using pME1 8 S
HDAC2 as template. Primers (50-phosphorylated) were as follows: forward,
50-AAGAAGACAGATGTTAGGGAAGAAGACAAATCC-30 , reverse, 50-GGATT
TGTCTTCTTCCCTAACATCTGTCTTCTTG-30 .
Luciferase constructs: Oct6 full SCE, Oct6 DHR1 SCE #3 and #19 (ref. 35; kind
gifts from Dies Meijer), Krox20-MSE8 pGL3-TATA43 (gift from Jerry Crabtree,
Addgene #21261). We generated Oct6 DHR2 SCE by PCR using the following
primers: forward, 50-CCGGCCGATATCTCAATGACTCACTCCTGATGG-30,
reverse, 50-CCGGCCGTCGACTCCTTTCAGCCTTCTGTTCC-30. The PCR
product was digested with EcoRV and SalI, and inserted into pGL3-promoter
vector (Promega) that was ﬁrst digested with BamH1, blunted and digested again
with SalI.
Constructs for in situ hybridization probes: pBluescript-Krox20 (kind gift from
Piotr Topilko), P0 (kind gift from G. Lemke and R. Axel), pBluescript-Oct6 (kind
gift from Dies Meijer). Newly generated constructs were veriﬁed by sequencing.
Cell culture. Puriﬁed primary rat Schwann cell (RSC) cultures were obtained as
described44. Identity and purity was checked for each primary preparation by
immunoﬂuorescence of SC-speciﬁc markers (p75, Sox10, Oct6, Krox20, P0, MAG)
under proliferation and differentiation conditions. Mycoplasma contamination was
not tested, because of the low incidence of mycoplasma contamination in primary
cells, and because mycoplasma contamination results in inefﬁciency of transfection,
which we did not observe in our primary cells. RSCs were grown in proliferation
medium: DMEM containing 10% FCS (Gibco), 1:500 penicillin/streptomycin
(Invitrogen), 4 mgml 1 crude GGF (bovine pituitary extract, Bioconcept),
and 2 mM forskolin (Sigma), at 37 C and 5% CO2/95% air. Schwann cell
dedifferentiation and redifferentiation culture protocols were previously
described31. Brieﬂy, RSCs were ﬁrst growth-arrested in deﬁned medium (DM44)
for 8 to 15 h, then 1mM dbcAMP (Sigma) was added to induce differentiation.
Cells were incubated in this medium for another 3 days. The medium was then
changed to DM only without dbcAMP, and incubated in this medium for 3 days
(differentiation mimicking adult Schwann cell stage). To induce dedifferentiation,
cells were then changed to proliferation medium and incubated in this medium
for 24 h (dedifferentiating conditions) or 3 days (dedifferentiation). For
redifferentiating conditions, cells under dedifferentiation were changed to DM and
incubated for 8 to 15 h, then 1mM dbcAMP was added and cells were incubated
for another 24 h in this medium.
Luciferase gene reporter assay. This assay was conducted as previously
described18. When cells were assayed in dedifferentiating conditions, transfection
was carried out at the time of change to proliferation medium. When cells were
assayed in redifferentiating conditions, transfection was carried out at the time of
dbcAMP addition after dedifferentiation. Cells were lysed 24 h after transfection.
For some experiments, 0.6 mM Mocetinostat (at this concentration, Mocetinostat
is a speciﬁc inhibitor of HDAC1/2: IC50 for HDAC1¼ 0.15 mM, IC50 for
HDAC2¼ 0.29 mM; at higher concentrations, Mocetinostat is also active on
HDAC3: IC50 for HDAC3¼ 1.66 mM) or its vehicle was added to the cells at the
time of transfection.
qRT-PCR. Isolation of RNA was carried out using Trizol reagent (Invitrogen) and
cDNA was produced using M-MLV Reverse Transcriptase (Promega), according to
the manufacturers’ recommendations. Quantitative real-time PCR analyses were
performed with an ABI 7000 Sequence Detection System (Applied Biosystems)
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14272 ARTICLE
NATURE COMMUNICATIONS | 8:14272 |DOI: 10.1038/ncomms14272 | www.nature.com/naturecommunications 13
using FastStart SYBR Green Master (Roche), according to the manufacturer’s
recommendations. A dissociation step was added to verify the speciﬁcity of the
products formed. Primer sequences were as follows: for rat Oct6, forward 50-GGG
CACCCTCTACGGTAATG-30 , reverse 50-CACTTGTTGAGCAGCGGTTT-30; for
rat Gapdh, forward 50-GTATCCGTTGTGGATCTGACAT-30 , reverse 50-GCCTGC
TTCACCACCTTCTTGA-30 , for mouse Oct6, forward 50-AAGCAGTTCAAGCA
ACGACG-30 , reverse 50- CACGTTACCGTAGAGGGTGC-30 , for mouse Gapdh,
forward 50- CGTCCCGTAGACAAAATGGT-30 , reverse 50-TTGATGGCAACAA
TCTCCAC-30 .
Lentiviral production and transduction. To produce lentiviral particles,
HEK293T cells were co-transfected with each lentiviral construct Oct6 shRNA or
control shRNA together with the packaging constructs pLP1, pLP2 and pLP/VSVG
(Invitrogen) using Lipofectamine 2000 (Invitrogen), according to the recommen-
dations of the manufacturer (ViraPower Lentiviral Expression Systems Manual).
Lentiviruses were added to primary RSCs in DM 3 days before adding proliferating
medium for dedifferentiation. Rat Oct6 shRNA (TL712899D) and control shRNA
(TR30021) lentiviral constructs were purchased from Origene Technologies.
Semithin and ultrathin sections and electron microscopy. Mice were killed with
150mg kg 1 pentobarbital i.p. (Esconarkon; Streuli Pharma AG) and sciatic
nerves were ﬁxed in situ with 3% paraformaldehyde and 0.15% glutaraldehyde in
0.1M phosphate buffer, pH 7.4. Fixed tissues were post-ﬁxed in 2% osmium
tetroxide, dehydrated through a graded acetone series as described previously45,
and embedded in Spurr’s resin (Electron Microscopy Sciences). Semithin sections
were stained with 1% Toluidine blue for analysis at the light microscope, and
ultrathin sections (70-nm thick) were made, as described45. All analyses were done
at 5mm distal to the lesion site. No contrasting reagent was applied. Images were
acquired using a Philips CM 100 BIOTWIN equipped with a Morada side-
mounted digital camera (Olympus).
Chromatin immunoprecipitation. Sciatic nerves were processed as described46
(preparation for ChIPseq), with modiﬁcations. Brieﬂy, chromatin was fragmented
by sonication with a Bioruptor (Diagenode) set at medium power, interval:
30 s on/45 s off, time: 4 cycles of 10min, rest of 2min between cycles. Sonicated
chromatin containing 75 mg of proteins and 3 mg of antibodies were used per
immunoprecipitation (IP). Quantitative real-time PCR analyses were performed
with an ABI 7000 Sequence Detection System (Applied Biosystems) using FastStart
SYBR Green Master (Roche), according to the manufacturer’s recommendations.
A dissociation step was added to verify the speciﬁcity of the products formed.
Primers sequences were as follows: Oct6 SCE HR2, forward, 50-CCACTGGGGA
GTCCTTCAA-30 , reverse, 50-TCTCAATGCCAAGGGAGGG-30 , Krox20 MSE,
forward, 50-TTTCGTCTTTGGGCTCATTC-30 , reverse, 50-AGCCCTTCACAAAG
CTGAAA-30.
For ChIP carried out with rabbit antibodies, we used rabbit anti-GFP antibody
as control IP (¼Neg IP), and for ChIP carried out with mouse antibodies, we used
mouse anti-Flag antibody as Neg IP.
Immunoﬂuorescence. Mouse sciatic nerves were ﬁxed in situ with 4% PFA for
10min, dissected, embedded in O.C.T. Compound (VWR chemicals), and frozen at
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 80 C. Sciatic nerve cryosections (5-mm thick) were ﬁrst incubated with acetone
for 10min at  20 C, washed in PBS/0.1% Tween 20, blocked for 30min at room
temperature (RT) in blocking buffer (0.3% Triton X-100/ 10% Goat serum/
phosphate buffer saline¼ PBS), and incubated with primary antibodies overnight
at 4 C in blocking buffer. For staining of HDAC1 or HDAC2, cryosections were
ﬁrst incubated with 70% Ethanol for 5min at RT, washed with PBS and incubated
for 40 s with 40 mgml 1 Proteinase K, before incubation with blocking buffer.
Sections were then washed three times in blocking buffer and secondary antibodies
were incubated for 1 h at RT in the dark. Sections were washed again, incubated
with DAPI for 5min at RT, washed and mounted in Citiﬂuor (Agar Scientiﬁc).
For whole-mount staining, nerves were processed as described47, with the
following modiﬁcations: sciatic nerves were ﬁxed in 4% paraformaldehyde for 1 h
at 4 C. For blocking and antibody incubations, we used the following buffer: 10%
goat serum/1% Triton X-100/PBS.
Primary antibodies: HDAC1 (rabbit, 1:200, Genetex, cat. #GTX100513),
HDAC2 (rabbit, 1:100, Santa Cruz Biotechnology, cat. #sc-7899), Oct6
(rabbit, 1:200, kind gift from Dies Meijer), Krox20 (rabbit, 1:100, Axxora, cat.
#CO-PRB-236P-100), JMJD2C (rabbit, 1:200, Abcam, cat. #ab85454), KDM3A
(rabbit, 1:200, Proteintech, cat. #12835-1-AP), P0 (chicken, 1:500, Aves Labs,
cat. #PZO), Neuroﬁlament (chicken, 1:500, GeneTex, cat. #GTX85461; rabbit,
1:200, Millipore, cat. #AB1987), cJun (rabbit, 1:200, Abcam, cat. #ab32137),
Sox2 (mouse, 1:100, Millipore, cat. #SC1002), GDNF (rabbit, 1:200, Abcam, cat.
#ab18956), GAP-43 (rabbit, 1:500, Abcam, cat. #ab75810). All secondary antibodies
were from Jackson ImmunoResearch. Photos were acquired using a Leica TCS
SP-II confocal microscope. Single optical sections or z-series projections (stated in
the ﬁgure legends) are shown. Axonal regrowth was measured using NeuronJ
software (ImageJ plugin freely available online with a user manual:
http://www.imagescience.org/meijering/software/neuronj/). Parameters used were
the same as described in the method validation article48: Neurite appearance:
Bright, Hessian smoothing scale: 2.0, Cost weight factor: 0.7, Snap window size:
9 9, Path-search window size: 2,500 2,500, Tracing smoothing range: 5, Tracing
subsampling factor: 5, Line width: 1.
In situ hybridization. In situ hybridization with digoxigenin (DIG)-labelled
riboprobes was carried out on cryosections (10-mm thick) as described49.
Hybridization signals were visualized with NBT/BCIP (Roche Diagnostics).
Antisense riboprobes were labelled with digoxigenin according to the
manufacturer’s instructions (Roche Diagnostics).
BrdU and EdU assays. BrDU was injected to mice 2 h prior killing. BrdU assays
were carried out as follows: cryosections were post-ﬁxed for 15min in 4% PFA at
RT, washed in PBS, incubated with 2M HCl for 10min at 37 C, rinsed in ddH2O,
washed with PBS, digested for 40 s with 40 mgml 1 Proteinase K, washed once
with PBS and twice with 0.1% Tween/PBS. Sections were then blocked with 30%
goat serum in PBS for 1 h at RT and incubated with BrDU antibody (Roche
Diagnostics) in blocking buffer overnight at 4 C. After three washes with PBS, the
secondary antibody (Alexa488 Goat anti-mouse, Jackson ImmunoResearch) was
incubated for 1 h in blocking buffer at RT. The sections were washed again in PBS,
labelled with DAPI, and mounted in Citiﬂuor. For double-labelling with F4/80
antibody, cryosections were ﬁrst labelled for F4/80 as described above in the
immunoﬂuorescence protocol, then they were processed for BrdU labelling. For
EdU assays (Click-iT Plus EdU Imaging Kits, Life Technologies), the EdU was
added to primary RSCs 1 h before ﬁxation, and the assay was conducted according
to the instructions of the manufacturer.
Western blot and immunoprecipitation. For all in vivo western blots and
immunoprecipitations, we have collected the injured sciatic nerve from the lesion
site to around 12mm distal to the lesion site (region where the nerve splits into the
three branches of tibial, sural and common peroneal nerves). We have collected the
same region of the contralateral nerve as internal control for each animal. After
perineurium removal, sciatic nerves were frozen in liquid nitrogen, pulverized with
a chilled mortar and pestle, lysed in radioimmunoprecipitation assay (RIPA) buffer
(10mM Tris/HCl, pH 7.4, 150mM NaCl, 50mM NaF, 1mM NaVO4, 1mM
EDTA, 0.5% wt/vol sodium deoxycholate, and 0.5% Nonidet P-40) for 15min on
ice, and centrifuged to pellet debris. Supernatants were collected, and protein
concentration was determined by Lowry Protein assay (Bio-Rad Laboratories).
Cells were washed once in PBS, lysed in RIPA buffer for 15min on ice, and
centrifuged to pellet debris. Sciatic nerves and cell lysates were submitted to SDS-
PAGE and analysed by western blotting. Images have been cropped for
presentation. Full-size images are presented in Supplementary Figs 17–23.
Primary antibodies used: HDAC1 (rabbit, 1:1,000, Genetex, cat. #GTX100513),
HDAC2 (mouse, 1:1,000, Sigma, cat. #H2663), Sox10 (rabbit, 1:250, DCS
Innovative Diagnostik-Systeme, cat. #SI058C01), GAPDH (glyceraldehyde-3-
phosphate-dehydrogenase, mouse, 1:5,000, Genetex, cat. #GTX28245), P0 (chicken,
1:1,000, Aves Labs, cat. #PZO), Krox20 (rabbit, 1:500, Axxora, cat.
#CO-PRB-236P-100), Oct6 (rabbit, 1:2,000, kind gift from Dies Meijer), Sox2
(mouse, 1:250, Millipore, cat. #SC1002), Pax3 (mouse, 1:1,000, Developmental
Studies Hybridoma Bank), cJun (mouse, 1:2000, BD Bioscience, cat. #610327),
beta-actin (mouse, 1:5,000, Sigma, cat. #A5441), JMJD2C (rabbit, 1:500, Abcam,
cat. #ab85454), KDM3A (mouse, 1:500, Abcam, cat. #ab91252; rabbit, 1:500,
Abnova, cat. #PAB16817).
All secondary antibodies were from Jackson ImmunoResearch: light-chain-
speciﬁc goat anti-mouse-HRP (horse radish peroxidase) and goat anti-rabbit-HRP,
and heavy-chain-speciﬁc goat anti-chicken-HRP.
For non-denaturing IPs, tissues were prepared and lysed as described in the
following RIPA buffer: 10mM Tris/HCl, pH 7.4, 150mM NaCl, 50mM NaF,
100mM Na3VO4, 1mM EDTA, 0.5% Na deoxycholate, 0.5% NP40. For
denaturing IPs, tissues were lysed in 10mM Tris/HCl, pH 7.4, 1% SDS, boiled,
mixed with nine volumes of RIPA buffer, reboiled, and centrifuged. Lysates were
pre-cleared for 1 h with 30 ml protein A/G PLUS agarose beads (Santa Cruz
Biotechnology). One millilitre of cleared lysates was rotated overnight at 4 C with
immunoprecipitating antibodies: 2 mg of Sox10 (rabbit, DCS Innovative
Diagnostik-Systeme, cat. #SI058C01), KDM3A (mouse, Abcam, cat. #ab91252),
JMJD2C (rabbit, Abcam, cat. #ab85454), SUMO-1 (clone D-11 mouse, Santa Cruz
biotechnology, cat. #sc-5308), HDAC2 (mouse, Sigma, cat. #H2663), acetyl-lysine
(rabbit, Abcam, cat. #ab21623), GFP (rabbit, Abcam, cat. #ab290) or Flag (clone
M2 mouse, Sigma, cat. #F1804) antibodies were used per nerve. When IPs were
carried out with rabbit antibodies, we used rabbit anti-GFP antibody as control IP.
When IPs were carried out with mouse antibodies, we used mouse anti-Flag
antibody as control IP. Forty microlitres of beads were added, and samples were
rotated for 1 h at 4 C. Immunoprecipitates were pelleted, washed four times with
RIPA buffer, eluted with 15 ml 0.1% formic acid and neutralized with 1.5M Tris,
pH 8.0. Six microlitres of Laemmli buffer were added and samples were boiled for
10min. Analysis was done by western blot.
Mass spectrometry analyses. Mass spectrometry data have been deposited in the
ProteomeXchange Consortium via the PRIDE partner repository under accession
code PXD005383. Membrane pieces were blocked by incubation in 0.1M acetic
acid with 0.5% polyvinylpyrrolidone-40 (Sigma) for 30min at 40 C, washed ﬁve
times with pure water before protein reduction (50mM DTT) and alkylation
(50mM iodoacetamide) using 100ml aliquots for 30min at 37 C. Proteins were
digested in 15ml of 10 ng ml 1 trypsin solution in 40mM Tris/HCl pH 8.0 and 10%
(v/v) acetonitrile. Digestions were stopped by addition of 10 ml 20% (v/v) TFA.
Proteins from agarose pull-downs were in-solution digested with 100 ng
sequencing grade trypsin (Promega) for 6 h at 37 C after the following treatment:
the dry beads were suspended in 30 ml of 8M urea in 50mM Tris/HCl, pH 8.0,
followed by reduction of the proteins with 3 ml 0.1M DTT for 30min at 37 C and
alkylation by addition of 3 ml 0.5M iodoacetamide for 30min at 37 C in the dark,
and urea dilution to 2M by addition of 20mM Tris/HCl pH 8.0 containing 2mM
CaCl2. Digestion was stopped by adding 1/20 of volume of 20% (v/v) TFA. An
aliquot of 5 ml of each digest was analysed by LC-MS/MS on an EASY-nLC1000
chromatograph connected to a QExactive HF mass spectrometer (Thermo Fisher
Scientiﬁc) using three replicate injections in case of the in-solution digests. Peptides
were trapped on a Pepmap100 Trap C18 300 mm 5mm (Thermo Fisher
Scientiﬁc) and separated by backﬂush onto the analytical column (C18 Aqua
Magic, 3 mm, 100Å, 75mm 150mm) with a 20 or 40min gradient from 5 to 40%
solution B (95% acetonitrile, 0.1% formic acid) at a ﬂow rate of 300 nlmin 1. Full
MS (resolution 60,000, automatic gain control target of 1e6, maximum injection
time of 50ms) and top15 MS/MS (resolution 15,000, target of 1e5, 110ms) scans
were recorded alternatively in the range of 400–1,400 m/z, with an inclusion
window of 1.6 m/z, relative collision energy of 27, and dynamic exclusion for 20 s.
Fragment spectra data were converted to mgf with ProteomeDiscoverer 2.0 and
peptide identiﬁcation made with EasyProt software, and processed with
MaxQuant/Andromeda version 1.5.0.0 (MQ) searching against the forward and
reversed UniprotKB SwissProt mouse protein database (Release 2014_01) with the
following parameters: parent mass error tolerance of 10 p.p.m., trypsin cleavage
mode with two missed cleavages, static carbamidomethylation on Cys, variable
oxidation on Met and acetylation on Lys. On the basis of reversed database peptide
spectrum matches, a 1% false discovery rate was set for acceptance of target
database matches.
Data availability. All relevant data are available from the authors.
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